Melanoma accounts for only about 1% of skin cancers, yet it causes the vast majority of skin cancer deaths. The reason comes down to biology: melanoma cells are uniquely equipped to spread early, evade the immune system, and survive the journey to distant organs. While other common skin cancers rarely travel beyond their original site, melanoma can seed itself in the lungs, liver, brain, and bones, sometimes before the spot on your skin looks alarming.
Melanoma Cells Are Built to Travel
Most skin cancers, like basal cell carcinoma and squamous cell carcinoma, grow slowly and almost never spread to distant organs. Melanoma is fundamentally different. The cells that give rise to melanoma, called melanocytes, descend from a group of embryonic cells known as the neural crest. During fetal development, neural crest cells are naturally migratory, traveling long distances through the body to become nerve cells, heart muscle cells, and pigment-producing skin cells. Melanoma cells retain this ancestral ability to move. They can reactivate the same molecular programs their precursor cells used during development, giving them an inherent talent for invasion that basal and squamous cell cancers simply don’t have.
This migratory heritage also makes melanoma cells highly adaptable. They can shift between different cellular states, a property called plasticity, which helps them invade new tissues, resist treatment, and thrive in environments very different from the skin where they started.
How Melanoma Survives in the Bloodstream
Spreading through the body is actually hard for cancer cells. The bloodstream is a hostile environment, full of oxidative stress that destroys most tumor cells before they can land anywhere new. Melanoma has found a workaround. Research from the University of Texas Southwestern showed that melanoma cells capable of efficient spread produce high levels of a transporter protein that pulls in lactate from the blood. This fuel source helps the cells neutralize oxidative damage while they circulate, dramatically improving their odds of surviving the trip and establishing new tumors in distant organs. Patients whose melanomas had high levels of this transporter had significantly worse survival outcomes.
This metabolic trick is one reason melanoma punches so far above its weight. Where other cancers might send millions of cells into the bloodstream with very few surviving, melanoma cells are better equipped for the journey.
Genetic Mutations That Fuel Rapid Growth
Between 40% and 60% of melanomas carry a mutation in a gene called BRAF, which acts like a stuck accelerator pedal for cell growth. When BRAF is mutated, it sends constant “grow and divide” signals to the cell, even when no normal growth signal is present. This drives rapid, uncontrolled tumor expansion.
The high frequency of this mutation has one silver lining: it created a target for treatment. Drugs that block the mutated BRAF protein can slow or shrink tumors in patients who carry the mutation. But the mutation itself is a core part of why melanoma can progress so quickly in the first place, especially in younger patients where BRAF mutations are particularly common.
Melanoma Tricks the Immune System
Your immune system should, in theory, recognize and kill cancer cells. Melanoma is unusually good at shutting that response down. Melanoma cells display a surface protein that acts like an “off switch” for attacking immune cells. When a T cell (the immune system’s main cancer killer) encounters this protein, it receives a signal to stop proliferating, stop attacking, and in some cases, self-destruct. The tumor essentially tells your immune system to stand down.
Melanoma goes further than just flipping one switch. It also recruits regulatory immune cells that actively suppress anti-tumor responses and produces enzymes that push the local immune environment toward tolerance rather than attack. The result is a tumor that grows in a self-created zone of immune suppression, even as the rest of your body’s defenses function normally. This is why immunotherapy, which removes these “off switches,” has been so transformative for melanoma treatment.
Lymph Nodes Act as Incubators
One of the more unsettling aspects of melanoma is how it uses your own lymph nodes against you. Before melanoma cells even arrive, the primary tumor sends chemical signals that prepare nearby lymph nodes to receive them. These signals trigger the growth of new lymphatic vessels in the node and create a pocket of local immune suppression, essentially rolling out a welcome mat.
Once melanoma cells settle in a lymph node, they find a protected environment where they can grow, accumulate additional mutations, and develop the ability to spread even further. A lymph node harboring melanoma cells for one to two years before detection can serve as a launchpad for distant metastasis that might have been prevented by earlier removal. This “incubator” effect helps explain why melanoma can appear in distant organs even when the original skin lesion seemed small or was caught relatively early.
Thickness Determines Everything
The single most important factor in predicting whether melanoma will spread is how deep it has grown into the skin, measured in millimeters. This measurement, called Breslow depth, directly correlates with the risk of metastasis and death.
- Less than 1 mm: Generally low risk, with excellent survival rates.
- 1 to 2 mm: Intermediate risk, where the chance of spread starts to climb.
- 2 to 4 mm: High risk, classified as at least Stage II.
- Greater than 4 mm: Very high risk, classified as Stage III even without confirmed spread to lymph nodes.
Ulceration, where the skin over the melanoma breaks down, worsens the prognosis at every depth. A 3 mm melanoma with ulceration is staged higher than a 3 mm melanoma without it. The problem is that aggressive subtypes, particularly nodular melanoma, can reach dangerous depths fast. Some fast-growing melanomas can penetrate to high-risk depths in as little as one month, leaving a very narrow window for detection.
How Quickly Outcomes Change by Stage
The survival gap between early and late-stage melanoma is one of the starkest in all of oncology. Based on data from patients diagnosed between 2015 and 2021, the five-year relative survival rates tell the story clearly:
- Localized (confined to the skin): Greater than 99%
- Regional (spread to nearby lymph nodes): 76%
- Distant (spread to remote organs): 35%
That drop from 99% to 35% is the core of why melanoma is so dangerous. A cancer that is nearly 100% survivable when caught early becomes life-threatening once it reaches distant organs. And because melanoma can spread when the primary tumor is still small and easy to overlook, many patients don’t get diagnosed at the localized stage. Roughly 3% to 10% of patients first present with metastatic disease without any obvious primary skin lesion at all.
Treatment Has Improved Dramatically
The good news is that even advanced melanoma is far more treatable than it was a decade ago. Before modern immunotherapy, patients with inoperable Stage IV melanoma had a median survival of just six to nine months. Today, combination immunotherapy that releases the immune system’s brakes has pushed median survival to nearly six years for the same group of patients.
This improvement is remarkable, but it underscores a key point: melanoma’s danger lies in its ability to reach that advanced stage in the first place. The biology that makes it lethal, its migratory origins, its metabolic resilience in the blood, its talent for immune evasion, and its use of lymph nodes as staging grounds, all work together to create a cancer that can outrun detection. Catching it early, when it’s still thin and localized, remains the single most powerful factor in survival.